TGen and Lilly Link Mutant AKT1 Genes to Three Common Cancers
Researchers from Translational Genomics Research Institute (TGen) and Eli Lilly & Company (NYSE: LLY) have discovered a mutation of the AKT1 gene which appears to cause tumor cell proliferation in breast, colorectal, and ovarian cancers.
The team identified the altered form of AKT1 by analyzing the molecular features of tumor samples from 150 cancer patients. The insights gained about AKT1′s involvement in the tumorigenic process will be useful in guiding development efforts for future cancer drugs and may also help doctors determine why some cells are resistant to current therapies.
According to the study’s lead author, John D. Carpten, PhD,
“The next step is to determine the prevalence of the AKT1 mutation in different populations and, hopefully, use the information gained to stratify patients going into clinical trials for AKT inhibitors.”
More information on this study can be found in the advance online publication of the international journal Nature.
Source: TGen News
Print This
|
|
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URI
Leave a comment
Browse All Categories: Next article: Swedish Team Shows Endometriosis Substantially Increases Risk of Certain Cancers
Previous article: The WHO Presents: 10 Facts About Cancer
